WESTCHESTER COUNTY LIFE SCIENCES UPDATE

IN THE NEWS

34 Westchester Teens Among the US's 300 Top Teen Scientists Chosen in Regeneron Science Talent Search

Society for Science announced the top 300 scholars in the Regeneron Science Talent Search 2023, the nation’s oldest and most prestigious science and math competition for high school seniors. The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar.

The Regeneron Science Talent Search scholars were selected from 1,949 applications from 627 high schools across 48 states, Washington, D.C., Puerto Rico and four other countries. Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders demonstrated through the submission of their original, independent research projects, essays and recommendations. The 300 scholars hail from 194 American and international high schools in 35 states and China.

Thirty four of the students selected are from Westchester County. The full list of scholars can be viewed here: Top 300 STS Scholars.

2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors

2seventy bio, Inc. announced an amendment to its collaboration with Tarrytown headquartered Regeneron Pharmaceuticals, Inc. that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors. The collaboration will leverage 2seventy bio’s unique cell therapy engineering and early-stage development capabilities, including the newly built in-house clinical cell therapy manufacturing facility, with Regeneron’s differentiated antibodies and bispecifics.

To support this expanded clinical development plan Regeneron will make a $20 million equity investment in 2seventy bio at a 50% premium and another approximately $20 million in near-term pre-clinical and clinical milestones. The parties will continue sharing costs for these activities in a manner largely consistent with the existing agreement, with Regeneron covering 75% of certain preclinical costs necessary to study combinations and 100% of the costs for the arms of clinical studies that include Regeneron agents through regulatory approval. For other programs, cost-sharing will follow the existing 50/50 cost sharing agreement.

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases



White Plains-headquartered Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.”

The ‘776 patent further strengthens the company’s intellectual property position and coverage for their tau oligomer formation inhibitors and provides product protection for Oligomerix’s lead clinical candidate, OLX-07010, including composition of matter and methods of use until October 2037.

IN THE NEWS

Cognition Therapeutics Announces New 'Conversations' Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer's Disease

Cognition Therapeutics Inc., has released its second 'Conversations' video podcast, featuring a virtual fireside discussion with neuroscience experts who share their perspective on clinical data recently presented at the 2022 CTAD conference in San Francisco, and implications for future Alzheimer's disease clinical research.

Episode 2: 'Building on Amyloid Lowering: Key Insights from Recent Data and Prospects for Complementary Therapeutic Approaches' is moderated by Anthony Caggiano, M.D., Ph.D., Cognition's chief medical officer and head of R&D, and features a conversation between:

Christopher H. van Dyck, M.D. – Yale University School of Medicine Professor of Psychiatry, Neurology, and Neuroscience; Director of the Yale School of Medicine Division of Aging and Geriatric Psychiatry; Director of the Alzheimer's Disease Research Center; and Anton P. Porsteinsson, M.D. – University of Rochester School of Medicine and Dentistry William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; Director of the Alzheimer's Disease Care, Research and Education Program (AD-CARE).

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

Purchase-headquartered Cognition Therapeutics, Inc. announced that the Phase 2 SHINE clinical trial of CT1812, an experimental oral, once-daily capsule in development for mild-to-moderate Alzheimer’s disease, has been expanded into clinical sites in Spain, the Netherlands, and the Czech Republic. CT1812 is designed to modulate a key cellular receptor known as sigma-2 and block oligomers from binding to neurons, thus preventing their synaptotoxic effects. This new mechanism of action is fundamentally distinct from and complementary with that of anti-amyloid antibody-based immunotherapy, such as lecanemab.

Results from initial trials with CT1812 provided evidence to support expansion of the clinical programs. In particular, positive trends were seen in cognition, MRI volumetric imaging and proteomic biomarkers:

• Slower decline in ADAS-cog vs placebo over six months
• Preservation of brain volume (composite) vs placebo with statistically significant (p<0.05) improvement in volume in three regions of interest
•  Normalization of biomarkers associated with Alzheimer’s pathology

Teladoc’s New Telehealth Offerings Looks to Better Integrate Primary Care, Behavioral Health Services

Telehealth giant Teladoc is integrating behavioral health and primary care in its new app. The app promises to help customers navigate care across Teladoc’s spectrum of services. It’s part of the company’s push to fully integrate services and move towards holistic care.



The app is being rolled out to specific clients this month and will be available to the full market later this year. Patients will be able to use the app to navigate services, review physician-based integration care plans and access care coordination tools with in-person providers. The Purchase headquartered company is also expanding its services to be available in English and Spanish.

EVENTS

All Access Healthcare: Regional Life Sciences Outlook

Date: February 2, 2023

Time: 8:30 AM - 10:00 AM

Register

Preparing for Entrepreneurship l Data: What the Innovation Community Expects

Date: February 2, 2023

Time: 5:30 PM

Register

Have good news to share from

Westchester’s life sciences ecosystem?

Please let us know.

Email lifesciences@westchestergov.com.